Advanced searches left 3/3

Dermatitis - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 23 July 2022

* If you want to update the article please login/register

Effect Of Using Oxygen On The Diaper Dermatitis In Infants

The purpose of our investigation was to determine the effects of oxygen on infant diaper dermatitis. Method: Infants will be admitted to the neonatal intensive care unit of a public hospital in Istanbul between May 2022 and September 2022, according to the study population. After each diaper change, Oxygen flow will be introduced to the experimental group for one hour. Every 24 hours, the severity of diaper dermatitis will be determined.

Source link: https://clinicaltrials.gov/ct2/show/NCT05427760


Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12)

Mild vs. moderately AD disease will be determined by gene expression profiles and transcriptomic endotypes on both study visits to determine the gene expression profiles and transcriptomic endotypes that characterized mild vs. moderately AD disease. AD skin endotypes associated with mild and moderate AD disease will also be investigated by the researchers. The primary aim of this study is to determine if the type 2-high non-lesional skin endotype is related to current mild versus moderately AD disease.

Source link: https://clinicaltrials.gov/ct2/show/NCT05436535


Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

AD in patients with clinical evidence of bacterial skin infections can be reduced by the use of dilute bleach baths. 09-HG-0059 Healthy volunteers aged 18 to 50 years with no history of AD No prior use of systemic antibiotics in the previous 12 months Subjects with atopic dermatitis with signs of active bacterial disease Objective SCORAD score of greater than or equal to 15 indicates moderate-to-severe disease design. BMC(01): A retrospective, placebo-controlled, investigator-blinded antimicrobial therapy shows improvements in microbiome from randomized, placebo- Subjects in Cohort 1 will be randomly assigned to one of the four open label antibiotic regimens. Subjects from Cohort 2 will be randomized to one of four potential blinded treatment regimen combinations of study baths and antibiotics. AD patients will be screened for skin infections related to medical therapy, and will be tested for responses of skin infections to treatment.

Source link: https://clinicaltrials.gov/ct2/show/NCT01631617


Quantification of Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis on Crisaborole Ointment, 2%

For a total of 540 participants, ranging from 3 months to 5 years and their primary caregivers, a total of 480 will be randomized in 1:1 proportion to either Crisaborole or vehicle therapy and will be followed for two weeks. The study will be based on an initial screening/baseline visit for children participants with an existing diagnosis of symptomatic AD, tested and enrolling in the trial together with their primary caregivers after signing an informed consent. Between the ages of 3 months to 5 years old, evaluate the effects of Crisaborole on itch and nighttime scratch in children with moderate to moderate AD. Secondary Objects: With mild to moderate AD, Evaluate the effects of Crisaborole on sleep in children ages 3 months to 5 years with mild to moderate AD. Assess the effect of crisaborole therapy on AD signs, symptoms, and severity in children aged 3 months to 5 years with mild to moderate AD. The investigation will include a screening/baseline visit on Day -7, an in-laboratory visit to tape-striping, and a final in-laboratory visit on Day 15 for an investigation of the AD, tape-stripping, completion of ObsROs, and return equipment on Day 15. Primary caregivers will be accompanied by children during all activities to ensure participant anonymity, and primary caregivers will be provided with ample time and a privacy curtain to change into a gown during testing for Atopic Dermatitis exclusion from the examination.

Source link: https://clinicaltrials.gov/ct2/show/NCT05200403


Study of the Effects on the Gut Microbiota in the Patients of Atopic Dermatitis Before and After the Treatment of Fucoidan.

Atopic dermatitis is an inflammatory disease in Taiwan, with about 6-7%. The patient's skin is triggered to release inflammatory precursor chemicals and inflammatory cells to the skin of the lesion's skin, triggering adhesion molecules to increase exudation of inflammatory precursor substances and inflammatory cells; Th0 also promotes differentiation of Th0 in the skin and blood of the lesion to Th2. The non-affected skin will also grow more Th2 via leukocytes expressing IgE, which will cause more allergic response in the acute phase. External use of steroid ointments will quickly dehydrate the skin, and is not recommended for long-term use. In recent years, the effects of intestinal bacteria on human immune function has become more and more understood. Immunity factors include: Segmented filamentous bacteria that aid in the differentiation of Th17 and Clostridium spp. It has not been reported in a Hothe investigatorsver, whether fucoidan will have an effect on the human gut after taking it. Fucoidan may have immunomodulatory effects on atopic dermatitis with immunomodulatory effects, according to our previous studies, but whether it is related to changes in gut bacteria is unclear. This study is designed to see if improving symptoms in patients with atopic dermatitis by fucoidan is related to intestinal flora change. Therefore, this prospective trial's findings are intended to investigate further fucoidan use in patients's atopic dermatitis--the effects of gut bacteria in patients. At the same time, the clinical effects of fucoidan on patients with atopic dermatitis can be tested again.

Source link: https://clinicaltrials.gov/ct2/show/NCT05437887


A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous Phase 2 And 3 EDP1815 Trials

Atopic dermatitis is a common skin disorder. Following participation in EDP1815-207, the number of participants will vary based on the number of participants who elect and are eligible to enroll in the Open Label Extension survey. Regardless of the treatment assignment in the EDP1815-207 study, all participants in this study will be treated with EDP1815. Participants may proceed from the parent study to the open label therapy phase without interruption of study analysis, or within 7 days of ending the parent study's study. If the participants enter this study directly without a break in care from the parent study, the Day -1 visit should be carried out at the same time as the parent study's end. During the treatment period and the parent study's study, the primary endpoint of safety and tolerability will be determined using the incidence and rate of 100 patient-years of treatment-emergent adverse events during the 36-week trial period and the 4-week follow-up period. All events starting with the first dose of study drug and on or before 28 days after each participant's last dose will be recorded. The number of courses of care with rescue therapies will also be determined, as well as antibiotic therapy due to skin infections, per participant.

Source link: https://clinicaltrials.gov/ct2/show/NCT05439941


A Randomized Clinical Trial Comparing Supplemental Topical Treatments for Acute Radiation Dermatitis in Breast Cancer Patients

The breast/chest wall determines the efficiency of Miaderm compared to Aquaphor in the treatment and/or prevention of radiation dermatitis in breast cancer patients undergoing EBRT. ARM I: Patients start using Aquaphor twice daily, but not within the four hours before EBRT, to the irradiated field two weeks after completion of EBRT. ARM II (MRT): Patients begin with Miaderm BID, but not within the four hours before EBRT, to the irradiated field two weeks following completion of EBRT, starting on day 1 of radiation therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT05340673

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions